Royalty Pharma

RPRX

Biotechnology · Healthcare

Price

$58.18

-0.35 (-0.60%)

Market Cap

$25.02B

Exchange

NASDAQ

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Share count rising — dilution

+34.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 414.8M (2021) → 559.6M (2025)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of r

Winston Score History

Politician Trades

2 trades / 12mo

0 Congressional buys and 2 sells on RPRX in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+11.0% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+23.6% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$452M/ year

↑ Rising (+22500% vs prior year)

19.0% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

4.6%ownership

Relatively low insider ownership

Cash Position

Cash flow positive

$586M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Royalty Pharma is putting 19% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

99.8%

Premium pricing power — 99.8% gross margin

Operating Margin

100.3%

Excellent — 100.3% operating margin

ROCE

4.0%

Weak — 4.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+7.8%

Steady sales growth (7.8% YoY)

EPS YoY

-0.2%

Earnings shrinking (-0.2% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

321%

Turns 321% of profit into real cash

FCF Margin

108.8%

Converts sales into free cash efficiently (108.8%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.30

Elevated debt (1.30)

Interest Cover

4.93x

Adequate interest coverage (4.9x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

23.6x

Growth-priced — P/E 23.6

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+15.1

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (23.6 → 8.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

1.69%

Small dividend — 1.69% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth

+5.8%

Dividend growing modestly (5.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial